Brief report · 29 Dec 2025
Conference abstractPublished 12 Sep 2011
Polycomb group genes as novel cancer biomarkers
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Polycomb group genes (PcGs) are epigenetic eff ectors involved in gene silencing. PcG activity was fi rst recognized as essential for stem cell maintenance during embryo development. Subsequently, several PcGs were shown to play a role in cancer initiation, progression, and chemotherapy resistance. For example, PcG member BMI1 is up-regulated in prostate cancer cells compared to normal counterparts, and mediates prostate cancer invasion and resistance to chemotherapy. Another PcG member (EZH2) is up-regulated in high grade and high stage breast, colorectal and brain tumors. At present, PcGs have been identifi ed as negative prognostic markers in most human cancers. Easy-to-perform genetic analyses may pave the way to the emergence of PcGs as cancer biomarkers. For example, Germinal EZH2 polymorphisms predict lung cancer risk and colorectal cancer prognosis. Somatic EZH2 mutations were found to drive B-cell lymphoma progression. In addition, a small molecule inhibitor of EZH2 showed promising anti-tumor activity in breast, brain and prostate tumor models. Th us, PcGs may emerge as novel prognostic and predictive markers in Oncology. Despite the well-recognized role of PCGs in cancer cell biology, few researches explored the clinical potential of these genes. In this presentation, I will summarize current evidence on PcGs and cancer, with particular emphasis on what they can add to traditional oncology biomarkers. In addition, I will illustrate a paradigm for rational development of PcG-targeting anticancer regimens, suggesting specifi c therapeutic strategies. Hopefully, PcGs may emerge as novel prognostic and predictive biomarker, as well as viable targets to target cancer initiation and metastatic spreading.
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Molecular Biomarkers & Diagnosis.
Commentary · 29 Dec 2025
Molecular Diagnostics: Revolutionizing Precision Healthcare
Commentary · 29 Dec 2025
Genomic Biomarkers Revolutionizing Disease Diagnosis and Medicine
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Molecular Biomarkers & Diagnosis
- SubjectGenetics & Molecular Biology
- SubjectPathology & Lab Medicine
- BylineArticles whose byline prints “Francesco Crea”
